Genzada in the News

Stay up-to-date on the latest research and scientific progress related to Genzada Pharmaceuticals and our pipeline of drug candidates.

First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02 from Genzada Pharmaceuticals

March 20, 2019

Genzada Pharmaceuticals USA Inc. announced today that the first patient enrolled in its Phase 1 clinical trial for the oral therapeutic GZ17-6.02 received the first dose this week at HonorHealth Research Institute in Scottsdale, Ariz.

Read More

Kansas Company Receives FDA Approval on Plant Derived Cancer Treatment

November 20, 2018

More than 600,000 people are expected to die from cancer this year, according to the National Cancer Institute. However, one Kansas company in Sterling is working to decrease that number and ultimately find a cure.

Read More